Completed PHASE4 INTERVENTIONAL 2-arm NCT00590044

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis

Sponsor: Emory University

Interventions NPH + Regular insulin insulin glargine+ glulisine

Updated 8 times since 2017 Last updated: Aug 30, 2018 Started: Dec 31, 2007 Primary completion: Jun 30, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Diabetic Ketoacidosis, this trial is completed. The trial is conducted by Emory University and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Oct 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Oct 2018 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University
Sanofi

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States
• Minneapolis, United States